ReviewPharmacogenomics2010
Pharmacogenetics of drug hypersensitivity.
Review in Pharmacogenomics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.Clinical pharmacology and therapeutics · 2012Guideline
- Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.The pharmacogenomics journal · 2018Trial
- Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.The pharmacogenomics journal · 2016Trial
- Antiepileptic Drug-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Case Series.Cureus · 2026Article
- Severe Cutaneous Adverse Reaction to Lamotrigine: A Case of Stevens-Johnson Syndrome in a Psychiatric Patient.Cureus · 2025Article
- The Australasian Registry for Severe Cutaneous Adverse Reactions (AUS-SCAR) - Providing a roadmap for closing the diagnostic, patient, and healthcare gaps for a group of rare drug eruptions.The World Allergy Organization journal · 2024Article
- A Singular Case Analysis: Lamotrigine-Associated Stevens-Johnson Syndrome.Case reports in critical care · 2024Article
- Article
- A Comprehensive Review on HIV-Associated Dermatologic Manifestations: From Epidemiology to Clinical Management.International journal of microbiology · 2023Review
- HLA-A*24:02 increase the risk of allopurinol-induced drug reaction with eosinophilia and systemic symptoms in HLA-B*58:01 carriers in a Korean population; a multicenter cross-sectional case-control study.Clinical and translational allergy · 2022Article
- Cefixime induced Steven Johnson syndrome: A case report from Bangladesh.Annals of medicine and surgery (2012) · 2022Article
- The Immunogenetics of Cutaneous Drug Reactions.Advances in experimental medicine and biology · 2022Article
- Drug allergy evaluation in children with suspected mild antibiotic allergy.Frontiers in allergy · 2022Article
- Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with Severe Cutaneous Adverse Reactions.Journal of clinical medicine · 2021Review
- Dual Antiepileptics Induced Stevens-Johnson Syndrome: A Case Report.JNMA; journal of the Nepal Medical Association · 2020Article
- A Rapid Allele-Specific Assay for HLA-A*32:01 to Identify Patients at Risk for Vancomycin-Induced Drug Reaction with Eosinophilia and Systemic Symptoms.The Journal of molecular diagnostics : JMD · 2019Article
- Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.Pharmacology & therapeutics · 2019Review
- Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention.Molecular diagnosis & therapy · 2018Review
- Review
- Pharmacogenomics of off-target adverse drug reactions.British journal of clinical pharmacology · 2017Review
Corrections and comments
- Erratum issuedErratum.2022
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Drug hypersensitivity reactions and severe cutaneous adverse drug reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, are examples of serious adverse drug reactions mediated through a combination of metabolic and immunological mechanisms that could traditionally not have been predicted based on the pharmacological characteristics of the drug alone. The discovery of new associations between these syndromes and specific HLA has created the promise that risk for these reactions could be predicted through pharmacogenetic screening, thereby avoiding serious morbidity and mortality associated with these types of drug reactions. Despite this, several hurdles exist in the translation of these associations into pharmacogenetic tests that could be routinely used in the clinical setting. HLA-B*5701 screening to prevent abacavir hypersensitivity syndrome is an example of a test now in widespread routine clinical use in the developed world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.